Hikma Pharmaceuticals (GB:HIK) has released an update.
Hikma Pharmaceuticals has reported a robust start to 2024, with positive performance across its three main business units and a reiteration of its full-year guidance of 4-6% revenue growth and a core operating profit between $660 million and $700 million. The company’s Injectables and Branded divisions are experiencing strong demand, with new product launches and market share gains in key therapeutic areas, while the Generics business is also showing solid performance with growth driven by a differentiated product portfolio. Additionally, Hikma announced a significant 29% increase in its 2023 full-year dividend, signaling confidence in its long-term growth prospects.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.
